Abstract:Class I HDACs are considered promising targets for cancer due to their role in epigenetic modifications. The main challenges in developing a new, potent and non-toxic class I HDAC inhibitor are selectivity and appropriate pharmacokinetics. The PROTAC technique (Proteolysis Targeting Chimera) is a new method in drug development for the production of active substances that can degrade a protein of interest (POI) instead of inhibiting it. This technique will open the era to produce selective and potent drugs with a high margin of safety. Previously, we reported different inhibitors targeting class I HDACs functionalized with aminobenzamide or hydroxamate groups. In the current research work, we will employ PROTAC technique to develop class I HDAC degraders based on our previously reported inhibitors. We synthesized two series of aminobenzamide-based PROTACs and hydroxamate-based PROTACs and tested them in vitro against class I HDACs. To ensure their degradation, all of them were screened against HDAC2 as representative example of class I. The best candidates were evaluated at different concentrations at various HDAC subtypes. This resulted in the PROTAC (32a) (HI31.1) that degrades HDAC8 with a DC50 of 8.9 nM with a proper margin of selectivity against other isozymes. Moreover, PROTAC 32a is able to degrade HDAC6 with DC50 = 14.3 nM. Apoptotic study on leukemic cells (MV-4-11) displayed more than 50 % apoptosis took place at 100 nM. PROTAC 32a (HI31.1) showed a good margin of safety against normal cell line and proper chemical stability.

Discovery and Functional Characterization of a Potent, Selective, and Metabolically Stable PROTAC of the Protein Kinases DYRK1A and DYRK1B

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders

Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (protacs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells.

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Discovery of a Potent and Selective JAK1-targeting PROTAC Degrader with Anti-Tumor Activities

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Probing class I histone deacetylases (HDAC) with proteolysis targeting chimera (PROTAC) for the development of highly potent and selective degraders

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases

Pan-KRAS destruction with a single PROTAC

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs.

Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS G12D

Selective Macrocyclic Inhibitors of DYRK1A/B.

Structural perspective on the design of selective DYRK1B inhibitors

Recent Advances in PROTACs for Drug Targeted Protein Research

Discovery of Novel BTK PROTACs for B-Cell Lymphomas.

Discovery of the First Selective and Potent PROTAC Degrader for the Pseudokinase TRIB2